Cumberland Pharmaceuticals Inc. (CPIX) News
Filter CPIX News Items
CPIX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest CPIX News From Around the Web
Below are the latest news stories about CUMBERLAND PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CPIX as an investment opportunity.
Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q3 2023 Earnings Call TranscriptCumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q3 2023 Earnings Call Transcript November 11, 2023 Operator: Good afternoon, and welcome to Cumberland Pharmaceuticals Third Quarter 2023 Company Update and Financial Report. This call is being recorded at Cumberland’s request and will be archived on the company’s website for one year from today’s date. I would now like to […] |
Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial ResultsCumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, announced today that its product portfolio of FDA-approved brands delivered combined revenues of $10.1 million during the third quarter of 2023 and $30.2 million year to date. |
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTSCumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the third quarter 2023 financial results and provide a company update after the market closes on Tuesday, Nov. 7, 2023. |
NEW VIBATV® PEDIATRIC PUBLICATION HIGHLIGHTS ITS SAFETY IN PATIENTS 2 TO 17 YEARS OF AGECumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today a new publication in Antimicrobial Agents and Chemotherapy1 detailing the results of the first clinical study investigating the safety and pharmacokinetics of Vibativ® (telavancin) injection in children 2 to 17 years of age. Vibativ is an intravenous antibiotic approved by the FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) as well as complicated skin and skin structure infections |
Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced significantly improved financial results and a favorable overall company performance for the second quarter of 2023. |
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTSCumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the second quarter 2023 financial results and provide a company update after the market closes on Tuesday, Aug. 8, 2023. |
NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTSCumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced the publication of positive results from a clinical study investigating the safety and pharmacokinetics of Caldolor® in newborn infants, published in the journal Pediatric Drugs1. Caldolor (ibuprofen) injection, is an intravenous non-steroidal anti-inflammatory drug (NSAID) approved by the FDA for the treatment of pain and fever in adults and children. The results of this published study supported |
CPIX: A Solid Stock with an Exciting CatalystBy Brad Sorensen, CFA NASDAQ:CPIX Cumberland Pharmaceuticals (NASDAQ:CPIX) is a company that has been around for over 20 years helping improve the quality of patient care through the delivery of high-quality prescription medicines. The company continues to do this quite well, and would make CPIX an interesting investment prospect, especially at recent prices, if that was the whole story. But it’s |
CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSISCumberland Pharmaceuticals Inc. (Nasdaq:CPIX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for a Phase II study in patients with Idiopathic Pulmonary Fibrosis, the most common form of progressive fibrosing interstitial lung disease. As a result, Cumberland will launch its FIGHTING FIBROSIS trial designed to enroll 128 patients in over 20 medical centers of excellence across the U.S. |
CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTSCumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved expanded labeling for Caldolor®, an intravenously delivered formulation of ibuprofen, to now include use in infants. The non-narcotic agent may now be administered for the treatment of pain and fever in patients three months to six months of age. |